Skip to main content
Top
Published in: Cancer Causes & Control 6/2010

01-06-2010 | Original paper

Clinical usefulness of glycosylated hemoglobin as a predictor of adenomatous polyps in the colorectum of middle-aged males

Authors: Beom Jin Kim, Young-Ho Kim, Dong Hyun Sinn, Ki Joo Kang, Jin Yong Kim, Dong Kyung Chang, Hee Jung Son, Poong-Lyul Rhee, Jae J. Kim, Jong Chul Rhee

Published in: Cancer Causes & Control | Issue 6/2010

Login to get access

Abstract

Objective

We investigated the clinical usefulness of HbA1c in screening an average-risk group <50 years of age who need colonoscopy for colorectal cancer (CRC) screening.

Methods

Eight hundred nineteen asymptomatic males who underwent colonoscopy for CRC screening with blood chemistries between January 2006 and December 2006 were enrolled. The ages of the subjects ranged from 40 to 59.

Results

Subjects in their 50 s had significantly more adenomatous polyps than subjects in their 40 s (32.7% vs. 26.0%, p < 0.05). The incidence of adenomatous polyp increased with increasing quartiles of HbA1C as follows: first quartile (19.9%, HbA1c 4.0–5.0), second quartile (27.8%, HbA1c 5.1–5.3), third quartile (32.7%, HbA1c 5.4–5.5), and fourth quartile (34.9%, HbA1c = 5.6–8.8)(p = 0.008). When combining quartile of HbA1c and age (40 s vs. 50 s) according to HbA1C levels, the odds ratio for adenomatous polyp in subjects in their 40 s with HbA1c <5.4% was significantly lower than that in subjects in their 50 s. However, the odds ratio for adenomatous polyp in subjects in their 40 s with HbA1c ≥5.4% was similar to that in subjects in their 50 s with average risk for CRC.

Conclusions

An elevated HbA1c may be useful as a clinical predictor of adenomatous polyps in male subjects <50 years of age who have average risk for CRC.
Literature
1.
go back to reference Shonka NA, Anderson JR, Panwalkar AW, Reed EC, Steen PD, Ganti AK (2006) Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer. Med Oncol 23:515–519CrossRefPubMed Shonka NA, Anderson JR, Panwalkar AW, Reed EC, Steen PD, Ganti AK (2006) Effect of diabetes mellitus on the epidemiology and outcomes of colon cancer. Med Oncol 23:515–519CrossRefPubMed
2.
go back to reference Chang CK, Ulrich CM (2003) Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 46:595–607CrossRefPubMed Chang CK, Ulrich CM (2003) Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 46:595–607CrossRefPubMed
3.
go back to reference Davila RE, Rajan E, Baron TH et al (2006) ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc 63:546–557CrossRefPubMed Davila RE, Rajan E, Baron TH et al (2006) ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc 63:546–557CrossRefPubMed
4.
go back to reference Ma J, Giovannucci E, Pollak M et al (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546–553PubMedCrossRef Ma J, Giovannucci E, Pollak M et al (2004) A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96:546–553PubMedCrossRef
5.
go back to reference Terry MB, Neugut AI, Bostick RM et al (2002) Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 11:622–629PubMed Terry MB, Neugut AI, Bostick RM et al (2002) Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 11:622–629PubMed
6.
go back to reference Myint PK, Sinha S, Wareham NJ et al (2007) Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship? Stroke 38:271–275CrossRefPubMed Myint PK, Sinha S, Wareham NJ et al (2007) Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship? Stroke 38:271–275CrossRefPubMed
7.
go back to reference Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ (2003) Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 12:412–418PubMed Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ (2003) Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 12:412–418PubMed
8.
go back to reference Blake GJ, Pradhan AD, Manson JE et al (2004) Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 164:757–761CrossRefPubMed Blake GJ, Pradhan AD, Manson JE et al (2004) Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 164:757–761CrossRefPubMed
9.
go back to reference Kaaks R, Toniolo P, Akhmedkhanov A et al (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592–1600CrossRefPubMed Kaaks R, Toniolo P, Akhmedkhanov A et al (2000) Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 92:1592–1600CrossRefPubMed
10.
go back to reference Shinchi K, Kono S, Honjo S et al (1994) Obesity and adenomatous polyps of the sigmoid colon. Jpn J Cancer Res 85:479–484PubMed Shinchi K, Kono S, Honjo S et al (1994) Obesity and adenomatous polyps of the sigmoid colon. Jpn J Cancer Res 85:479–484PubMed
11.
go back to reference Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E (1999) Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control 10:379–386CrossRefPubMed Platz EA, Hankinson SE, Rifai N, Colditz GA, Speizer FE, Giovannucci E (1999) Glycosylated hemoglobin and risk of colorectal cancer and adenoma (United States). Cancer Causes Control 10:379–386CrossRefPubMed
12.
go back to reference Rundle AG, Lebwohl B, Vogel R, Levine S, Neugut AI (2008) Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology 134:1311–1315CrossRefPubMed Rundle AG, Lebwohl B, Vogel R, Levine S, Neugut AI (2008) Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology 134:1311–1315CrossRefPubMed
13.
go back to reference Imperiale TF, Kahi CJ, Stuart JS et al (2008) Risk factors for advanced sporadic colorectal neoplasia in persons younger than age 50. Cancer Detect Prev 32:33–38CrossRefPubMed Imperiale TF, Kahi CJ, Stuart JS et al (2008) Risk factors for advanced sporadic colorectal neoplasia in persons younger than age 50. Cancer Detect Prev 32:33–38CrossRefPubMed
14.
go back to reference Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF (2002) Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 346:1781–1785CrossRefPubMed Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF (2002) Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 346:1781–1785CrossRefPubMed
15.
go back to reference Ikeda F, Doi Y, Yonemoto K et al (2009) Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 136:1234–1241CrossRefPubMed Ikeda F, Doi Y, Yonemoto K et al (2009) Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 136:1234–1241CrossRefPubMed
16.
go back to reference Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:s836–842PubMed Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:s836–842PubMed
17.
go back to reference Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO (1997) Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 89:660–661CrossRefPubMed Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO (1997) Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst 89:660–661CrossRefPubMed
18.
go back to reference Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC (1997) Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 57:4787–4794PubMed Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC (1997) Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 57:4787–4794PubMed
19.
go back to reference Will JC, Galuska DA, Vinicor F, Calle EE (1998) Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 147:816–825PubMed Will JC, Galuska DA, Vinicor F, Calle EE (1998) Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 147:816–825PubMed
20.
go back to reference O’Mara BA, Byers T, Schoenfeld E (1985) Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 38:435–441CrossRefPubMed O’Mara BA, Byers T, Schoenfeld E (1985) Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 38:435–441CrossRefPubMed
21.
go back to reference Hu FB, Manson JE, Liu S et al (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91:542–547CrossRefPubMed Hu FB, Manson JE, Liu S et al (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91:542–547CrossRefPubMed
22.
go back to reference La Vecchia C, Negri E, Decarli A, Franceschi S (1997) Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 6:1007–1010PubMed La Vecchia C, Negri E, Decarli A, Franceschi S (1997) Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 6:1007–1010PubMed
23.
go back to reference Tripkovic I, Tripkovic A, Ivanisevic Z, Capkun V, Zekan L (2004) Insulin increase in colon cancerogenesis: a case-control study. Arch Med Res 35:215–219CrossRefPubMed Tripkovic I, Tripkovic A, Ivanisevic Z, Capkun V, Zekan L (2004) Insulin increase in colon cancerogenesis: a case-control study. Arch Med Res 35:215–219CrossRefPubMed
24.
go back to reference Suehiro T, Matsumata T, Shikada Y, Sugimachi K (2005) Hyperinsulinemia in patients with colorectal cancer. Hepatogastroenterology 52:76–78PubMed Suehiro T, Matsumata T, Shikada Y, Sugimachi K (2005) Hyperinsulinemia in patients with colorectal cancer. Hepatogastroenterology 52:76–78PubMed
25.
go back to reference Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 13:915–919PubMed Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 13:915–919PubMed
Metadata
Title
Clinical usefulness of glycosylated hemoglobin as a predictor of adenomatous polyps in the colorectum of middle-aged males
Authors
Beom Jin Kim
Young-Ho Kim
Dong Hyun Sinn
Ki Joo Kang
Jin Yong Kim
Dong Kyung Chang
Hee Jung Son
Poong-Lyul Rhee
Jae J. Kim
Jong Chul Rhee
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 6/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9543-4

Other articles of this Issue 6/2010

Cancer Causes & Control 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine